# Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma

> **NCT01393340** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 23 (actual)

## Conditions studied

- Nasal Polyposis
- Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01393340
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-10
- **Final completion:** 2009-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2011-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01393340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01393340, "Clinical and Biological Effects of Anti-IgE (Omalizumab) in Patients With Bilateral Nasal Polyposis and Asthma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01393340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*